Immune markers study for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at immune markers in people with advanced non-small cell lung cancer (NSCLC) that cannot be cured. It tests how well the immune system responds to treatment, and may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (NSCLC) and cannot be cured with standard treatments.
- Your cancer does not have a specific gene mutation that can be targeted by special drugs.
- Your PD-L1 level (a measure of immune activity) is less than 50% on tumor cells.
- You are willing to have a biopsy (tissue sample) if needed for the study.
- For some patients: you have not yet had treatment for your lung cancer and are about to start immunotherapy or chemo-immunotherapy.
- For others: your cancer has gotten worse after your first immunotherapy or chemo-immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study is looking at how the immune system responds to immunotherapy in people with advanced non-small cell lung cancer. By collecting sputum (mucus from your lungs) and blood samples, researchers hope to find clues that could help predict treatment outcomes.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.